Moderna Forecast, price target & analysts
Moderna Target price 2025 - Analyst rating & recommendation
Moderna Classifications & Recommendation:
Moderna Price Target
| Target Price | $28.56 |
| Price | $27.97 |
| Potential |
2.11%
register free of charge
|
| Number of Estimates | 22 |
|
22 Analysts have issued a price target Moderna 2026 .
The average Moderna target price is $28.56.
This is
2.11%
register free of charge
$141.75
406.79%
register free of charge
$17.17
38.61%
register free of charge
|
|
| A rating was issued by 29 analysts: 4 Analysts recommend Moderna to buy, 18 to hold and 7 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Moderna stock has an average upside potential 2026 of
2.11%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 3.24 | 1.94 |
| 52.75% | 40.14% | |
| EBITDA Margin | -100.77% | -204.36% |
| 386.66% | 102.79% | |
| Net Margin | -110.04% | -167.68% |
| 59.86% | 52.38% |
27 Analysts have issued a sales forecast Moderna 2025 . The average Moderna sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Moderna EBITDA forecast 2025. The average Moderna EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
27 Moderna Analysts have issued a net profit forecast 2025. The average Moderna net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -9.27 | -8.31 |
| 24.88% | 10.36% | |
| P/E | negative | |
| EV/Sales | 3.35 |
27 Analysts have issued a Moderna forecast for earnings per share. The average Moderna EPS is
This results in the following potential growth metrics and future valuations:
Current Moderna Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Nov 21 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 21 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 21 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 23 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 23 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Nov 21 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 21 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 21 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 23 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 23 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
